Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Discover yearly leaders among index funds and understand how performance shifts across periods, helping you choose resilient options.
27,236 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Rocket Lab isn’t profitable yet, but the space company shows four clear catalysts for investors. Here are practical r...
A wave of state laws on private listings in housing is reshaping how loans and mortgages are marketed. Three regulato...
A high-profile insider sale at Sonic Automotive sparks questions about executive shareholdings and stock outlook. Thi...
Rivian shocks investors by cutting jobs shortly after starting to deliver the R2. This move raises questions about ho...
The weight loss therapy wave has fireworks at the giants, but smart investors look for underrated weight loss stocks ...
Ukraine’s drone strikes knock out a southern refinery and threaten fuel deliveries, prompting Putin to acknowledge a ...
SoFi is betting big on product innovation to lift growth. This deep dive explains what the latest move could mean for...
A public clash over music rights offers practical finance lessons. This article breaks down how licensing decisions i...
Airline equities tumbled in a broad market selloff after West Texas Intermediate crude surged, lifting fuel costs and...
Dogecoin shot to fame and then faded, but savvy investors still wonder about its future. This guide breaks down the o...
Two powerhouse ideas could propel your portfolio toward the next decade: a campus-wide AI infrastructure leader and a...